NEWS | Aug 17, 2021

LOK Corporation and Sense Neuro Diagnostics Announce Commercial Partnership Focused on International Market

(August 17, 2021—Montreal, Canada and Cincinnati, Ohio) LOK Corporation, a manufacturing agent that helps companies develop and manage their international distribution network and Sense Neuro Diagnostics, a medical technology company focused on improving outcomes for stroke and brain injury patients today announced a commercial partnership to bring innovative brain scanners being developed by Sense to the international market pending regulatory approval. Sense is developing non-invasive brain scanners to meet needs identified by the company’s medical co-founders, who are specialists in emergency medicine, neurology and neurocritical care.

NeuSTAT™ is currently in a pivotal trial for continuous monitoring of brain injury in an acute care setting.
NeuroHawk™ EMS (expected to begin pivotal trial in 2022) is being developed as a triage tool for first responders, enabling detection of traumatic brain injury and stroke by subtype.

“We believe that this technology is a long-awaited solution for the healthcare industry and that it will become the standard very quickly,” added Daniel Cloutier, CEO of LOK Corporation.

When it comes to stroke and brain injury, we often hear the expression “time is brain” because the typical patient loses 1.9 million neurons each minute in which stroke is untreated, and because stroke and brain injury treatments are time sensitive. Ongoing or repeat bleeding in the brain contributes to decreased brain function and disability and may be difficult to detect under the current standard of care. There is currently no objective way to detect brain injury and stroke subtype in a field environment, or to continuously monitor brain injury for expanded hemorrhage in the hospital.

Sense is developing non-invasive brain scanners that use low-power radiofrequency (RF) pulse to scan the brain in seconds to enable rapid detection of traumatic brain injury (TBI) and important stroke subtypes in a pre-hospital setting, and continuous brain injury monitoring between CT scans in hospital. First-in-human pilot studies of both devices have yielded promising results, paving the way for pivotal trials.

“As we advance toward market entry, Sense Neuro Diagnostics is excited to partner with the LOK corporation to enter the global marketplace beginning with India and Europe. The LOK team shares our vision for using innovative technology to improve outcomes for stroke and brain injury patients,” commented Geoff Klass, CEO of Sense Neuro Diagnostics.

About LOK Corporation

LOK Corporation is a manufacturing agent that helps companies develop and manage their international distribution network. Over the years, LOK has built a reputation representing major players such as Masimo, SoClean and Lidco, but also companies that were in their first steps of commercialization. LOK also offers training tools for the sales force and several other services to support sales & marketing.

About Sense Neuro Diagnostics

Sense Neuro Diagnostics is a medical technology company focused on improving outcomes for stroke and brain injury patients through technology innovations that enable faster detection and more effective triage. Sense is developing non-invasive technology to enable continuous, real-time brain injury monitoring as well as rapid detection of traumatic brain injury and important stroke subtypes—ischemic stroke with large vessel occlusion, ischemic stroke without large vessel occlusion, and intracerebral hemorrhage. Learn more at https://senseneuro.com or find Sense Neuro Diagnostics on LinkedIn or Twitter @SenseDx.